-
公开(公告)号：US11719710B2
公开(公告)日：2023-08-08
申请号：US16695713
申请日：2019-11-26
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Andrea Horsch , Dietmar Zdunek , Georg Hess
CPC classification number: G01N33/74 , C07K14/4716 , G01N33/6863 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/52 , G01N2800/347 , G01N2800/50 , G01N2800/52
Abstract: The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.
-
公开(公告)号：US20230030564A1
公开(公告)日：2023-02-02
申请号：US17772959
申请日：2020-10-27
Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
Inventor： Andrea Horsch , Eberhard Spanuth
Abstract: The present invention concerns methods for aiding in the risk assessment of a patient with suspected sepsis. For example, the risk of poor outcome (such as of a complicated clinical course and/or of mortality) can be assessed. The methods of the present invention may comprise the steps of (a) determining the amount of the biomarker Presepsin in a sample from a patient with suspected sepsis who has a known qSOFA (quick Sequential Organ Failure-Assessment) score of 0, 1, 2 or 3, (b) determining the amount of the biomarker Pro-calcitonin (PCT) in a sample from the patient, comparing the amounts determined in steps (b) and (c) to reference amounts, and (d) aiding in the risk assessment of a patient with suspected sepsis. The methods of the present invention may be computer-implemented.
-
公开(公告)号：US20170082639A1
公开(公告)日：2017-03-23
申请号：US15358779
申请日：2016-11-22
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N33/6872 , G01N33/74 , G01N2333/47 , G01N2333/475 , G01N2800/347 , G01N2800/56
Abstract: Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.
-
公开(公告)号：US09535073B2
公开(公告)日：2017-01-03
申请号：US13713719
申请日：2012-12-13
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Georg Hess , Andrea Horsch , Dietmar Zdunek
CPC classification number: G01N33/6893 , G01N33/6872 , G01N33/74 , G01N2333/47 , G01N2333/475 , G01N2800/347 , G01N2800/56
Abstract: Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.
Abstract translation: 用于预测与受试者的外科手术相关的急性肾损伤AKI有关的不良事件风险的系统，试剂盒和方法。 该系统和方法的实施方案包括用于测定样品（例如受试者的尿液样品）中肝型脂肪酸结合蛋白（L-FABP）的量的方法和步骤; 将L-FABP的量与参考量进行比较，并且预测与受试者的外科手术相关的与急性肾损伤有关的不良事件的风险。
-
5.发明申请USE OF BIOMARKERS IN THE ASSESSMENT OF THE EARLY TRANSITION FROM ARTERIAL HYPERTENSION TO HEART FAILURE 审中-公开生物标记在评估从早期转移到心脏失效的早期转换中的使用公开(公告)号：US20140065648A1
公开(公告)日：2014-03-06
申请号：US13776314
申请日：2013-02-25
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Ursula-Henrike Wienhues-Thelen , Dirk Block , Hendrik Heudig , Sabine Vogel-Ziebolz , Christine Boehm , Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: G01N33/68
CPC classification number: G01N33/54306 , G01N33/6887 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/58 , G01N2800/325 , G01N2800/50 , G01N2800/52
Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
Abstract translation: 用于诊断心脏衰竭前的心脏的功能和/或结构异常以及用于预测心脏衰竭发展的风险的方法和系统，包括测量样品中的心肌肌钙蛋白并将测量值与参考值进行比较。 在一些实施方案中也测量了其它标志物，包括GDF15和IGFBP7。
-
Patent Agency Ranking
公开(公告)号：US20200333360A1
公开(公告)日：2020-10-22
申请号：US16916809
申请日：2020-06-30
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Georg Hess , Andrea Horsch , Dietmar Zdunek
Abstract: The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
-
公开(公告)号：US10732188B2
公开(公告)日：2020-08-04
申请号：US14291676
申请日：2014-05-30
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC: A61K38/00 , C12Q1/68 , G01N33/567 , G01N33/74 , G01N33/68
Abstract: The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
-
公开(公告)号：US20180231570A1
公开(公告)日：2018-08-16
申请号：US15943104
申请日：2018-04-02
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Andrea Horsch , Birgit Klapperich , Dirk Block , Alfred Engel , Johann Karl , Rosemarie Kientsch-Engel , Ekaterina Manuilova , Christina Rabe , Sandra Rutz , Monika Soukupova , Ursula-Henrike Wienhues-Thelen , Peter Kastner , Edelgard Anna Kaiser
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N33/68 , G01N33/74 , G01N2333/47 , G01N2333/8139 , G01N2800/347 , G01N2800/50
Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.
-
9.发明申请GDF-15 and/or Troponin T for Predicting Kidney Failure in Heart Surgery Patients 审中-公开GDF-15和/或肌钙蛋白T预测心脏手术患者的肾衰竭公开(公告)号：US20160109464A1
公开(公告)日：2016-04-21
申请号：US14856543
申请日：2015-09-16
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Andrea Horsch , Dietmar Zdunek , George Hess
CPC classification number: G01N33/74 , C07K14/4716 , G01N33/6863 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/52 , G01N2800/347 , G01N2800/50 , G01N2800/52
Abstract: The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.
Abstract translation: 本公开涉及实验室诊断领域。 具体地，公开了用于基于检测GDF-15，肌钙蛋白T和/或利尿钠肽来确定在外科手术后患有急性肾损伤的患者的风险的手段和方法。
-
公开(公告)号：US20140274793A1
公开(公告)日：2014-09-18
申请号：US14291676
申请日：2014-05-30
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Georg Hess , Andrea Horsch , Dietmar Zdunek
CPC classification number: G01N33/74 , G01N33/6893 , G01N33/6896 , G01N2333/58 , G01N2800/2871 , G01N2800/50
Abstract: The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
Abstract translation: 本发明涉及一种用于诊断怀疑显示出暂时缺血发作，但没有发生中风的受试者的暂时缺血发作（TIA）的方法。 该方法基于来自所述受试者的样品中NT-proANP的量的确定。 此外，本发明涉及基于来自受试者的样品中NT-proBNP和NT-proANP的量的确定来诊断受试者的急性脑缺血事件的方法。 该方法还包括计算NT-proBNP和NT-proANP的量的比例的步骤。 本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.021 seconds)
